Springhill Fund Asset Management HK Co Ltd Takes $4.21 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 151,200 shares of the company's stock, valued at approximately $4,206,000. Akero Therapeutics accounts for approximately 6.8% of Springhill Fund Asset Management HK Co Ltd's investment portfolio, making the stock its 8th biggest holding. Springhill Fund Asset Management HK Co Ltd owned 0.22% of Akero Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of AKRO. AlphaQuest LLC increased its holdings in Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after buying an additional 8,147 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Akero Therapeutics in the 4th quarter valued at about $303,000. KLP Kapitalforvaltning AS acquired a new position in Akero Therapeutics in the 4th quarter worth about $306,000. XTX Topco Ltd purchased a new position in Akero Therapeutics during the third quarter worth approximately $308,000. Finally, Proficio Capital Partners LLC acquired a new stake in Akero Therapeutics in the fourth quarter valued at approximately $320,000.

Insider Buying and Selling

In other news, COO Jonathan Young sold 607 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the sale, the chief operating officer now directly owns 200,540 shares of the company's stock, valued at approximately $9,000,235.20. The trade was a 0.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO William Richard White sold 676 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $30,338.88. Following the completion of the transaction, the chief financial officer now owns 61,959 shares in the company, valued at approximately $2,780,719.92. This represents a 1.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 341,309 shares of company stock valued at $15,863,578 and sold 248,385 shares valued at $12,289,029. Corporate insiders own 7.94% of the company's stock.

Remove Ads

Akero Therapeutics Trading Up 0.6 %

Shares of NASDAQ AKRO traded up $0.20 during trading on Friday, hitting $35.02. 209,032 shares of the company were exchanged, compared to its average volume of 854,857. The company has a fifty day moving average price of $45.27 and a 200-day moving average price of $35.81. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market capitalization of $2.79 billion, a PE ratio of -9.38 and a beta of -0.18. Akero Therapeutics, Inc. has a 12-month low of $17.86 and a 12-month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AKRO. Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Citigroup boosted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Finally, UBS Group raised their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics has a consensus rating of "Buy" and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.